Safety of immunosupressive therapy with or without denosumab in patients with rheumatoid arthritis

Trial Profile

Safety of immunosupressive therapy with or without denosumab in patients with rheumatoid arthritis

Completed
Phase of Trial: Phase IV

Latest Information Update: 15 Nov 2017

At a glance

  • Drugs Denosumab (Primary)
  • Indications Rheumatoid arthritis
  • Focus Adverse reactions
  • Most Recent Events

    • 15 Nov 2017 Results assessing occurrence of serious infection in patients with rheumatoid arthritis treated with immunosupressive therapy with or without denosumab, were published in The Journal of Rheumatology.
    • 25 Aug 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top